- £212.05bn
- £230.23bn
- $54.07bn
- 85
- 15
- 94
- 76
REG - AstraZeneca PLC - Enhertu granted BTD for post-neoadjuvant early BC
AnnouncementREG - AstraZeneca PLC - Update on LATIFY Phase III trial of ceralasertib
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Subcutaneous Saphnelo approved in EU
AnnouncementREG - AstraZeneca PLC - Enhertu approved in US for 1L HER2+ metastatic BC
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Block listing Interim Review
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in US for early gastric cancer
AnnouncementREG - AstraZeneca PLC - AstraZeneca manufacturing investment in Maryland
AnnouncementREG - AstraZeneca PLC - Koselugo (selumetinib) approved in the US
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - 9M and Q3 2025 results
AnnouncementREG - AstraZeneca PLC - Result of General Meeting
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Director Declaration
AnnouncementREG - AstraZeneca PLC - Koselugo (selumetinib) approved in the EU
Announcement